Maze Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAZE research report →
Range $64 – $97
Price Chart
About the company
Maze Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
- CEO
- Jason Coloma
- IPO
- 2025
- Employees
- 141
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on MAZE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.60B
- P/E
- -10.56
- PEG
- 0.20
- P/S
- 80.06
- P/B
- 3.77
- EV/EBITDA
- -11.20
- Div Yield
- 0.00%
- Gross Margin
- 95.28%
- Op Margin
- -728.06%
- Net Margin
- -667.95%
- ROE
- -34.94%
- ROIC
- -28.35%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-2,403,000-101.4%
- Op Income
- $-142,899,000
- Net Income
- $-131,120,000-351.0%
- EPS
- $-3.05-4020.3%
- OCF Growth
- -247.4%
- FCF Growth
- -250.7%
- 52W High
- $53.65
- 52W Low
- $12.91
- 50D MA
- $27.92
- 200D MA
- $34.43
- Beta
- 2.21
- RSI (14)
- 55
- Avg Volume
- 562.91K
No earnings-call transcripts are available for MAZE yet.
- Free Float
- 28.9%
- Shares Outstanding
- 55.35M
- Float Shares
- 15.98M
of shares held by institutions
145 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 2.86M | ▼ 283.71K |
| Vanguard Group Inc | 1.70M | ▲ 362.06K |
| Congress Wealth Management LLC / De / | 30.23K | ▲ 30.23K |
| Two Sigma Advisers, LP | 14.80K | ▲ 14.80K |
| Cibc Private Wealth Group, LLC | 5.40K | ▲ 5.40K |
| Cwm, LLC | 2.14K | ▼ 86 |
| California State Teachers Retirement System | 1.44K | ▲ 114 |
| Sunbelt Securities, Inc. | 12 | 0 |
Held by 167 ETFs
Biggest fund positions in MAZE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 26 | Kornowski Sophie | other | 36,000 |
| Aug 13, 26 | Johnson Paula A | other | 36,000 |
| Aug 13, 26 | Kornowski Sophie | other | 0 |
| Aug 13, 26 | Johnson Paula A | other | 0 |
| Aug 13, 26 | Bernstein Harold | other | 16,142 |
| Aug 13, 26 | Bernstein Harold | other | 16,142 |
| Aug 13, 26 | Bernstein Harold | sell | 16,142 |
| Aug 3, 26 | Coloma Jason V | sell | 30,304 |
| Aug 3, 26 | Coloma Jason V | sell | 1,604 |
| Aug 3, 26 | Coloma Jason V | sell | 2,439 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MAZE coverage
Recent articles, reports, and earnings notes.
No research on MAZE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAZE report →Maze Therapeutics Announces Appointments to Its Board of Directors
globenewswire.com · Aug 13
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
globenewswire.com · Aug 11
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
zacks.com · Jul 21
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
fool.com · Jun 29
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 10
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
globenewswire.com · May 27
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
globenewswire.com · May 27
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
fool.com · May 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.